Cargando…
Biologics for Psoriasis During the COVID-19 Pandemic
Coronavirus disease 2019 (COVID-19), a new form of acute infectious respiratory syndrome first reported in 2019, has rapidly spread worldwide and has been recognized as a pandemic by the WHO. It raised widespread concern about the treatment of psoriasis in this COVID-19 pandemic era, especially on t...
Autores principales: | Zeng, Huanhuan, Wang, Siyu, Chen, Ling, Shen, Zhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685238/ https://www.ncbi.nlm.nih.gov/pubmed/34938746 http://dx.doi.org/10.3389/fmed.2021.759568 |
Ejemplares similares
-
Biologics for Psoriasis during the COVID-19 Pandemic
por: Kamiya, Koji, et al.
Publicado: (2021) -
Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China
por: Zhao, Liang, et al.
Publicado: (2021) -
Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study
por: Huang, Dawei, et al.
Publicado: (2023) -
Risk of Herpes Zoster Among Psoriasis Patients Taking Biologics: A Network Meta-Analysis of Cohort Studies
por: Tang, Zhenwei, et al.
Publicado: (2021) -
Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
por: Wang, Juncheng, et al.
Publicado: (2023)